Vimarsana
Biggest News Aggregation in the World

Page 2 - Client Alert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Client Alert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Client Alert Today - Breaking & Trending Today

Key Questions for the Upcoming Private Funds Rules Fifth Circuit Decision | Goodwin - Vimarsana News

Key Questions for the Upcoming Private Funds Rules Fifth Circuit Decision | Goodwin

As a reminder, the Securities and Exchange Commission (SEC) and the National Association of Private Fund Managers (NAPFM) and the other Petitioners in the Private Funds Rules...

FTC's Final Rule Prohibits Non-Competes With Employees - Employee Rights/ Labour Relations - Vimarsana News

FTC's Final Rule Prohibits Non-Competes With Employees - Employee Rights/ Labour Relations

On April 23, 2024, the FTC voted to adopt a rule prohibiting employers from entering into non-competes with workers employed by companies over which the FTC...

Source: mondaq.com
Legal Reform on Electronic Negotiable Instruments | White & Case LLP - Vimarsana News

Legal Reform on Electronic Negotiable Instruments | White & Case LLP

On March 26, 2024, a decree was published in the Mexican Federal Official Gazette amending, adding, and repealing certain provisions of the General Law on Negotiable Instruments and...

LDT Final Rule: Shifting the LDT Battlefield | King & Spalding - Vimarsana News

LDT Final Rule: Shifting the LDT Battlefield | King & Spalding

On April 29, 2024, the Food and Drug Administration (“FDA” or “the Agency”) released a pre-publication version of the highly anticipated laboratory developed test final rule (“LDT Final...

Red Alert On The Orange Book: The FTC Continues To Crack Down On Improperly Listed Drug Patents - Patent - Vimarsana News

Red Alert On The Orange Book: The FTC Continues To Crack Down On Improperly Listed Drug Patents - Patent

As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration's "Approved Drug Products...

Source: mondaq.com